Express Scripts (ESRX) updated its FY13 earnings guidance on Tuesday. The company provided EPS guidance of $4.20-4.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.21.
Several analysts have also recently commented on the stock. Analysts at JPMorgan Chase reiterated an overweight rating on shares of Express Scripts in a research note to investors on Friday. They now have a $68.00 price target on the stock. On a related note, analysts at TheStreet reiterated a buy rating on shares of Express Scripts in a research note to investors on Wednesday, February 13th. Finally, analysts at Raymond James reiterated an outperform rating on shares of Express Scripts in a research note to investors on Tuesday, February 12th. They now have a $62.00 price target on the stock.
Thirteen investment analysts have rated the stock with a buy rating, one has assigned an overweight rating, and three have issued a hold rating to the stock. The company presently has a consensus rating of buy and an average price target of $62.96.
Shares of Express Scripts (ESRX) opened at 55.57 on Tuesday. Express Scripts (ESRX) has a 52 week low of $49.79 and a 52 week high of $66.06. The stock’s 50-day moving average is currently $54.62. The company has a market cap of $45.367 billion and a P/E ratio of 33.26.
Express Scripts, Inc. is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
